PAVmed

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.

NEW YORK--( BUSINESS WIRE )-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”, the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D., PAVmed's Chairman and CEO, will participate in the Technologies Ushering in Next-Generation Diagnostics, Therapies, and Surgeries virtual panel discussion on November 21, 2022 from 12:00 pm to 12:55 pm EST at the BTIG Digital Health Forum. Dr. Aklog will, in part, discuss PAVmed's majority-owned digital health subsidiary, Veris Health.

PAVmed to Participate in BTIG Digital Health Forum

Lucid Diagnostics

NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Lishan Aklog, M.D.

Lucid Diagnostics to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the commencement of production of its EsoCheck® Esophageal Cell Collection Devices (“EsoCheck”) at Coastline International, Inc. (“Coastline”), a high-volume manufacturer headquartered in San Diego, CA with plants in Mexico.

Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer

NEW YORK--(BUSINESS WIRE)---- $PAVM #1x1meetings--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical device company today announced that the Company will host a business update conference call and webcast on Tuesday, November 15, 2022, at 4:30 PM EDT.

PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022

NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call and webcast on Monday, November 14, 2022, at 4:30 PM EDT.

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022

Acorda Therapeutics

Atossa Genetics

Atara Biotherapeutics

Xeris Biopharma Holdings

Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 Biotech Stocks For Your Watch List This Week

NEW YORK--(BUSINESS WIRE)---- $PAVM #1x1meetings--PAVmed to Participate in the Lake Street 6th Annual Best Ideas Growth Conference and the A.G.P. Virtual MedTech Conference

PAVmed to Participate in the Lake Street 6th Annual Best Ideas Growth Conference and the A.G.P. Virtual MedTech Conference

PAVmed Inc. (NASDAQ:PAVM ) Q2 2022 Earnings Conference Call August 16, 2022 4:30 PM ET Company Participants Adrian Miller - VP, IR Lishan Aklog - Chairman and CEO Dennis McGrath - President and CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Edward Woo - Ascending Capital Anthony Vendetti - Maxim Group Operator Greeting. Welcome to the PAVmed Inc. Second Quarter 2022 Business Update Conference Call.

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2022 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $LUCD #LUCD--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the three and six months ended June 30, 2022. Conference Call and Webcast A conference c

PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results

NEW YORK--(BUSINESS WIRE)---- $PAVM #PAVmed--PAVmed Inc. announced that the Company will host a business update conference call on Tuesday, August 16, 2022, at 4:30 PM EDT.

PAVmed to Hold a Business Update Conference Call on August 16, 2022

NEW YORK--(BUSINESS WIRE)---- $LUCD #checkyourfoodtube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that its wholly-owned CLIA-certified and CAP-accredited laboratory, LucidDx Labs Inc. (“LucidDx Labs”), has entered into participating provider agreements with preferred provider organizations Prime Healthcare, Three Rivers Provider Network, and G

Lucid Diagnostics' Laboratory Executes Four New Participating Provider Agreements

PAVmed established an interesting hub and spoke business model with joint services and selling stakes in commercially ready technologies. This opens up new financing streams and potentially a lot of value creation for PAVmed shareholders.

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

PAVmed Inc. (NASDAQ:PAVM ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Adrian Miller - VP, IR Lishan Aklog - Chairman and CEO Dennis McGrath - President and CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Jeremy Pearlman - Maxim Group Ed Woo - Ascendiant Capital Operator Good day and welcome to the PAVmed Inc. First Quarter Business Update Call. Today's conference is being recorded.

PAVmed Inc.'s (PAVM) CEO Lishan Aklog on Q1 2022 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $PAVM #PAVmed--PAVmed provides business update and preliminary first quarter 2022 financial results.

PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results

Blue Apron

Medavail Holdings Inc

Short squeeze penny stocks to watch this week. The post 3 Short Squeeze Penny Stocks To Buy For Under $5 This Week￼ appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Short Squeeze Penny Stocks To Buy For Under $5 This Week￼

Short squeeze penny stocks to watch this week. The post 3 Short Squeeze Penny Stocks To Buy For Under $5 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Short Squeeze Penny Stocks To Buy For Under $5 This Week

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced a procedural update on its settlement of a previously disclosed class action lawsuit.

PAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)---- $PAVM #businessupdate--PAVmed to hold a Business Update Conference Call on May 12, 2022.

PAVmed to Hold a Business Update Conference Call on May 12, 2022

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2021 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $PAVM #earnings--PAVmed provides business update and preliminary fourth quarter and full year 2021 financial results.

PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

PAVmed Inc (NASDAQ: PAVM) announced the successful implantation of its PortIO Intraosseous Infusion System in three patients as part of a first-in-human (FIH) clinical study of up to 40 patients. No complications have occurred.

PAVmed Highlights First-In-Human Implantations of its PortIO Infusion System

NEW YORK--(BUSINESS WIRE)---- $PAVM #PortIO--PAVmed announces successful first-in-human implantations of its PortIO™ Intraosseous Infusion System.

PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System

NEW YORK--(BUSINESS WIRE)---- $PAVM #DigitalHealth--PAVmed subsidiary Veris Health launches world-class technology advisory board.

PAVmed Subsidiary Veris Health Launches World-Class Technology Advisory Board

NEW YORK--(BUSINESS WIRE)---- $PAVM #Healthcare--PAVmed to hold a business update conference call on March 29, 2022.

PAVmed to Hold a Business Update Conference Call on March 29, 2022

The shares of the company are extremely volatile as visibility into the financial future of the company is limited. However, we do think that, while certainly not devoid of risk, the shares potentially contain much more value, given Lucid's addressable market and the rapid build-up of its commercial infrastructure.

News for PAVmed Stock (PAVM)